FDA notifications.  FDA approves raltegravir for HIV-1 treatment-naive patients.
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium